Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Clinical Laboratory, Taizhou Hospital, Wenzhou Medical University, Zhejiang, China.
Biomed Res Int. 2017;2017:9295313. doi: 10.1155/2017/9295313. Epub 2017 May 3.
Current studies of serum sclerostin levels in AS and RA patients are inconsistent. This meta-analysis was performed to identify the association of serum sclerostin level with AS and RA patients. Embase, PubMed, MEDLINE, and Cochrane Library databases (up to 25 January 2017) were used to collect all relevant published articles. Studies were pooled and standard mean difference (SMD) with 95% confidence interval (CI) was calculated. All data analyses were performed using RevMan 5.3. Totally eight studies of AS including 420 AS patients and 317 healthy controls (HC) and three studies of RA including 145 RA patients and 127 HC were finally included in this meta-analysis. The results revealed that the serum sclerostin levels in both AS patients (SMD = -0.14; 95% CI = [-0.39,0.11]; = 0.28) and RA patients (SMD = -0.10; 95% CI = [-0.34,0.15]; = 0.43) were not significantly different from those in HC. The difference of serum sclerostin levels in AS and RA patients was not significantly different from HC, indicating that the sclerostin may not associate with the development of AS and RA.
目前关于血清硬骨素水平在 AS 和 RA 患者中的研究结果并不一致。本荟萃分析旨在确定血清硬骨素水平与 AS 和 RA 患者的相关性。我们检索了 Embase、PubMed、MEDLINE 和 Cochrane Library 数据库（截至 2017 年 1 月 25 日），以收集所有相关的已发表文献。对纳入的研究进行汇总，并计算标准化均数差（SMD）及其 95%置信区间（CI）。使用 RevMan 5.3 进行所有数据分析。最终共有 8 项 AS 研究（共纳入 420 例 AS 患者和 317 例健康对照者）和 3 项 RA 研究（共纳入 145 例 RA 患者和 127 例健康对照者）纳入本荟萃分析。结果显示，AS 患者（SMD = -0.14；95%CI = [-0.39,0.11]； = 0.28）和 RA 患者（SMD = -0.10；95%CI = [-0.34,0.15]； = 0.43）的血清硬骨素水平与健康对照者相比差异均无统计学意义。AS 和 RA 患者血清硬骨素水平与健康对照者的差异无统计学意义，表明硬骨素可能与 AS 和 RA 的发病无关。
